BRCA2 and neoplasm: However, no significant differences were observed in pCR rates, tumor size or lymph node involvement between BRCA1-, BRCA2-PV and WT carriers, suggesting that the choice of treatment regimen does not necessarily translate into superior clinical outcomes.